Structural Profiling of Endogenous S-Nitrosocysteine Residues Reveals

Total Page:16

File Type:pdf, Size:1020Kb

Structural Profiling of Endogenous S-Nitrosocysteine Residues Reveals Structural profiling of endogenous S-nitrosocysteine residues reveals unique features that accommodate diverse mechanisms for protein S-nitrosylation Paschalis-Thomas Douliasa,1, Jennifer L. Greenea,1, Todd M. Grecoa, Margarita Tenopouloua, Steve H. Seeholzera, Roland L. Dunbrackb, and Harry Ischiropoulosa,2 aChildren’s Hospital of Philadelphia Research Institute and Department of Pharmacology, Children’s Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA 19104; and bProgram in Molecular Medicine, Fox Chase Cancer Center, Philadelphia, PA 19111 Edited by Michael A. Marletta, University of California, Berkeley, CA, and approved August 19, 2010 (received for review June 9, 2010) S-nitrosylation, the selective posttranslational modification of pro- appreciate the biological selectivity of this posttranslational modi- tein cysteine residues to form S-nitrosocysteine, is one of the fication. Attempts to investigate this very important biological molecular mechanisms by which nitric oxide influences diverse question have not been possible largely because datasets of in vivo biological functions. In this study, unique MS-based proteomic modified proteins are not available (1, 11). Previous structural approaches precisely pinpointed the site of S-nitrosylation in 328 analyses have been attempted using limited data sets or by including peptides in 192 proteins endogenously modified in WT mouse liver. all sites of modification identified after exposing tissues or cells to Structural analyses revealed that S-nitrosylated cysteine residues S-nitrosylating agents (11). However, as the authors of these articles were equally distributed in hydrophobic and hydrophilic areas of have indicated, these sites of modification represent putative sites ± proteins with an average predicted pKa of 10.01 2.1. S-nitrosylation but not necessarily those modified in vivo (11). We used organo- sites were over-represented in α-helices and under-represented in fi fi fi mercury reagents that react directly, ef ciently, and speci cally coils as compared with unmodi ed cysteine residues in the same pro- with S-nitrosocysteine and thus enable the precise identification teins (χ2 test, P < 0.02). A quantile–quantile probability plot indicated of S-nitrosocysteine–containing peptides and independently S- that the distribution of S-nitrosocysteine residues was skewed to- nitrosylated proteins to assemble the in vivo S-nitrosocysteine ward larger surface accessible areas compared with the unmod- ified cysteine residues in the same proteins. Seventy percent of the proteome of the mouse liver. By using bioinformatic tools, we then S-nitrosylated cysteine residues were surrounded by negatively or interrogated this enriched endogenous S-nitrosocysteine proteome fi positively charged amino acids within a 6-Å distance. The location of to de ne the biochemical, biophysical, and structural environment fi cysteine residues in α-helices and coils in highly accessible surfaces of the cysteine residues modi ed by S-nitrosylation, elements that bordered by charged amino acids implies site directed S-nitrosylation might inform on how specificity of S-nitrosylation is achieved. mediated by protein–protein or small molecule interactions. Moreover, 13 modified cysteine residues were coordinated with metals and Results and Discussion 15 metalloproteins were endogenously modified supporting metal- Complementary MS-Based Proteomics Identify the Endogenous Liver catalyzed S-nitrosylation mechanisms. Collectively, the endogenous S- S-Nitrosocysteine Proteome. The reaction of phenylmercury com- nitrosoproteome in the liver has structural features that accommodate pounds with S-nitrosocysteine results in the formation of a relatively multiple mechanisms for selective site-directed S-nitrosylation. stable thiol–mercury bond (12). Therefore, we used an organomercury resin (MRC) synthesized by conjugation of ρ-amino-phenylmercuric cysteine modification | nitric oxide | S-nitrosation | posttranslational acetate to N-hydroxysuccinimide–activated Affi-Gel 10 agarose modification | proteomics beads and a phenylmercury-polyethyleneglycol-biotin (mPEGb) compound to capture S-nitrosylated proteins and peptides (Fig. ysteine S-nitrosylation is a reversible and apparently selective S1). The method consists of three steps: (i) blocking of reduced Cposttranslational protein modification that regulates protein cysteine residues with methyl methanethiosulfonate (MMTS), (ii) activity, localization, and stability within a variety of organs and capture and release of S-nitrosylated proteins or peptides, and (iii) cellular systems (1–6). Despite the considerable biological impor- liquid chromatography/tandem MS analysis. β-Mercaptoethanol or tance of this posttranslational modification, significant gaps exist performic acid was used to release captured proteins or pep- regarding its in vivo specificity and origin. The identification of tides, respectively. Mild performic acid was used to selectively and in vivo S-nitrosylated proteins has indicated that not all reduced quantitatively release the bound peptides and more importantly cysteine residues and not all proteins with reduced cysteine residues oxidize cysteine thiols to sulfonic acid, thereby creating a unique are modified, implying a biased selection. Several biological MS signature that permits site-specific identification of the modi- chemistries have been proposed to account for the S-nitrosylation fied cysteine residues (13). Under the workflow used (Fig. S1), of proteins in vivo (1, 7, 8). Broadly, these include (i) oxidative 100% of cysteine-containing peptides were detected with the sul- S-nitrosation by higher oxides of NO, (ii) transnitrosylation by small fonic acid modification. molecular weight NO carriers such as S-nitrosoglutathione or dinitrosyliron complexes, (iii) catalysis by metalloproteins, and (iv) protein-assisted transnitrosation, as elegantly documented for the Author contributions: H.I. designed research; P.-T.D., J.L.G., M.T., and S.H.S. performed S-nitrosylation of caspase-3 by S-nitrosothioredoxin (9, 10). With research; P.-T.D., T.M.G., and H.I. contributed new reagents/analytic tools; P.-T.D., J.L.G., the exception of the protein-assisted transnitrosylation and metal- T.M.G., S.H.S., R.L.D., and H.I. analyzed data; and P.-T.D., J.L.G., T.M.G., and H.I. wrote the loprotein catalyzed S-nitrosylation, which we presume necessitates paper. protein–protein interaction, the other proposed mechanisms are The authors declare no conflict of interest. rather nondiscriminatory unless the microenvironment of selective This article is a PNAS Direct Submission. cysteine residues in proteins can specifically accommodate these 1P.-T.D. and J.L.G. contributed equally to this work. chemical modifications. Therefore, structural interrogation of en- 2To whom correspondence should be addressed. E-mail: [email protected]. fi fi dogenous S-nitrosylated proteins with site speci cidenti cation of This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. the modified cysteine residues could provide valuable insights to 1073/pnas.1008036107/-/DCSupplemental. 16958–16963 | PNAS | September 28, 2010 | vol. 107 | no. 39 www.pnas.org/cgi/doi/10.1073/pnas.1008036107 Downloaded by guest on September 26, 2021 To control for the inclusion of false-positive protein S- nitrosocysteine with the phenylmercury compounds is specificand nitrosocysteine that may result from incomplete blocking of re- efficient and achieved selective identification of the modified res- duced cysteine residues or nonspecific interactions with the resins idue, the ultimate qualifier for the unambiguous assignment of S- during enrichment, pretreatment with UV, DTT, and copper- nitrosylated proteins through the inclusion of negative controls. ascorbate (Cu-Asc) reduction or reaction with mercury chloride The ability of the method to reveal endogenous S- were used to displace NO before the reaction with the phenyl- nitrosoproteomes was assessed in WT mouse liver homogenates. mercury compounds (Fig. 1A and Fig. S2A). For these experi- Initially, three different mouse livers were analyzed independently ments, we used mouse liver homogenates with 50 ± 10 pmol for protein and peptide capture by using both the MRC and protein S-nitrosocysteine per milligram of protein as quantified by mPEGb approach with 3 mg of starting material. From the three reductive chemistries coupled to ozone-based chemiluminescence. biological replicates, sulfonic acid-containing peptides identified Displacement of NO from S-nitrosocysteine residues by pre- by SEQUEST database searches were pooled and those also treatment with UV, DTT, Cu-Asc, or mercury chloride decreased present in the UV-pretreated samples were removed. Similarly, all protein S-nitrosocysteine levels by greater than 99% as quantified proteins identified by protein capture were pooled (those also by chemiluminescence (n = 3) and also eliminated reaction with identified in the UV-pretreated samples were removed). The use the phenylmercury compounds (Fig. 1A and Fig. S2A). On average, of solid-phase and in-solution–based enrichment approaches was only 3% of peptides (Fig. 1B) and 5% of proteins (Fig. S2B) largely complementary, as the number of shared protein identi- were identified as false positives (present in untreated and UV- fications between protein capture methods was approximately pretreated samples), demonstrating that the method maintains 50%, whereas each method individually contributed about the high specificity at each step.
Recommended publications
  • Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents
    Novel “Add-On” Molecule Based on Evans Blue Confers Superior Pharmacokinetics and Transforms Drugs to Theranostic Agents Haojun Chen*1,2, Orit Jacobson*2, Gang Niu2, Ido D. Weiss3, Dale O. Kiesewetter2, Yi Liu2, Ying Ma2, Hua Wu1, and Xiaoyuan Chen2 1Department of Nuclear Medicine, Xiamen Cancer Hospital of the First Affiliated Hospital of Xiamen University, Xiamen, China; 2Laboratory of Molecular Imaging and Nanomedicine, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, Maryland; and 3Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland One of the major design considerations for a drug is its The goal of drug development is to achieve high activity and pharmacokinetics in the blood. A drug with a short half-life in specificity for a desired biologic target. However, many potential the blood is less available at a target organ. Such a limitation pharmaceuticals that meet these criteria fail as therapeutics because dictates treatment with either high doses or more frequent doses, of unfavorable pharmacokinetics, in particular, rapid blood clearance, both of which may increase the likelihood of undesirable side effects. To address the need for additional methods to improve which prevents the achievement of therapeutic concentrations. For the blood half-life of drugs and molecular imaging agents, we some drugs, the administration of large or frequently repeated doses developed an “add-on” molecule that contains 3 groups: a trun- is required to achieve and maintain therapeutic levels (1) but can, in cated Evans blue dye molecule that binds to albumin with a low turn, increase the probability of undesired side effects.
    [Show full text]
  • Solutions to 7.012 Problem Set 1
    MIT Biology Department 7.012: Introductory Biology - Fall 2004 Instructors: Professor Eric Lander, Professor Robert A. Weinberg, Dr. Claudette Gardel Solutions to 7.012 Problem Set 1 Question 1 Bob, a student taking 7.012, looks at a long-standing puddle outside his dorm window. Curious as to what was growing in the cloudy water, he takes a sample to his TA, Brad Student. He wanted to know whether the organisms in the sample were prokaryotic or eukaryotic. a) Give an example of a prokaryotic and a eukaryotic organism. Prokaryotic: Eukaryotic: All bacteria Yeast, fungi, any animial or plant b) Using a light microscope, how could he tell the difference between a prokaryotic organism and a eukaryotic one? The resolution of the light microscope would allow you to see if the cell had a true nucleus or organelles. A cell with a true nucleus and organelles would be eukaryotic. You could also determine size, but that may not be sufficient to establish whether a cell is prokaryotic or eukaryotic. c) What additional differences exist between prokaryotic and eukaryotic organisms? Any answer from above also fine here. In addition, prokaryotic and eukaryotic organisms differ at the DNA level. Eukaryotes have more complex genomes than prokaryotes do. Question 2 A new startup company hires you to help with their product development. Your task is to find a protein that interacts with a polysaccharide. a) You find a large protein that has a single binding site for the polysaccharide cellulose. Which amino acids might you expect to find in the binding pocket of the protein? What is the strongest type of interaction possible between these amino acids and the cellulose? Cellulose is a polymer of glucose and as such has many free hydroxyl groups.
    [Show full text]
  • An Investigation of D-Cycloserine As a Memory Enhancer NCT00842309 Marchmay 23, 15, 2016 2019 Sabine Wilhelm, Ph.D
    MayMarch 23, 2016 15, 2019 An investigation of D-cycloserine as a memory enhancer NCT00842309 MarchMay 23, 15, 2016 2019 Sabine Wilhelm, Ph.D. May 23, 2016 1. Background and Significance BDD is defined as a preoccupation with an imagined defect in appearance; if a slight physical anomaly is present, the concern is markedly excessive (American Psychiatric Association [APA], 1994). Preoccupations may focus on any body area but commonly involve the face or head, most often the skin, hair, or nose (Phillips et al., 1993). These preoccupations have an obsessional quality, in that they occur frequently and are usually difficult to resist or control (Phillips et al., 1998). Additionally, more than 90% of BDD patients perform repetitive, compulsive behaviors (Phillips et al., 1998), such as frequent mirror checking (Alliez & Robin, 1969), excessive grooming (Vallat et al., 1971), and skin picking (Phillips & Taub, 1995). Accordingly, a core component of Cognitive-Behavioral treatment for BDD is exposure and response prevention (ERP). Exposure and response prevention involves asking patients to gradually expose themselves to situations that make them anxious (e.g. talking to a stranger, going to a party) while refraining from engaging in any rituals (e.g. excessive grooming or camouflaging) or safety behaviors (e.g. avoiding eye contact). Rituals and safety behaviors are thought to maintain the fear response because they prevent the sufferer from staying in contact with the stimulus long enough for his or her anxiety to extinguish. By exposing the patient to the feared situation while preventing the rituals and safety behaviors, the patient’s anxiety is allowed to naturally extinguish and he is able to acquire a sense of safety in the presence of the feared stimulus.
    [Show full text]
  • Genefor the De Novo
    Agric. Biol. Chem., 47 (10), 2405~2408, 1983 2405 Rapid Paper B; these two proteins are collectively termed quinolinate synthetase, (2) Protein B converts Synthesis of Quinolinic Acid by aspartic acid to an intermediate capable of the EnzymePreparation of undergoing condensation with DHAP cata- Escherichia coli Which Contains lyzed by Protein A, (3) Proteins A and B are coded by nadA and nadB, respectively, and (4) a Plasmid Carrying the nad the quinolinate synthetase system is subjected Gene for the de novo to feedback inhibition as well as end product Synthesis of NAD repression. An outline of quinolinic acid syn- thesis is shown in Fig. 1. Intermediates of Masaaki Kuwahara, Mizuyo Yonehana, quinolinic acid synthesis, however, have not Tetsuhiro Kimura and Yutaka Ishida yet been isolated in pure forms except for butynedioic acid and its amination product2) Department of Food Science, KagawaUniversity, which are proposed to be intermediates. Our Miki-cho, Kagawa 761-07, Japan experiment aimed to elucidate the inter- Received March 17, 1983 mediary metabolism of the de novo pathway for NADsynthesis using recombinant DNA A plasmid, pNADHl, carrying the nad gene for the de techniques with an E. coli host-vector system. novo synthesis of NADwas constructed with pBR322 and chromosomal DNAof Escherichia coli. Cleavage by re- MATERIALS AND METHODS striction endonucleases showed that the plasmid contained a DNAinsert of 8.9 Kbp at the Hin&lll site ofpBR322. Strains. Escherichia coli C600 (F~, thr~, leu", thi ~, m~, The cell-free extract of a transformant of E. coli C600 r~, LacY) and HB101 carrying plasmid pBR322 were which contained the plasmid formed 5 times more quinol- provided by Prof.
    [Show full text]
  • Differential Control of Steroidogenesis by Nitric Oxide and Its Adaptation with Hypoxia
    259 THEMATIC REVIEW eNOS activation and NO function: Differential control of steroidogenesis by nitric oxide and its adaptation with hypoxia Charles A Ducsay and Dean A Myers1 Center for Perinatal Biology, Loma Linda University School of Medicine, Loma Linda, California 92350, USA 1Department of Obstetrics and Gynecology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73190, USA (Correspondence should be addressed to C A Ducsay; Email: [email protected]) Abstract Nitric oxide (NO) plays a role in a wide range of physiological regulation of NO synthases in specific endocrine tissues processes. Aside from its widely studied function in the including ovaries, testes, and adrenal glands. The effects of regulation of vascular function, NO has been shown to hypoxia on generation of NO and subsequent effects on impact steroidogenesis in a number of different tissues. The steroid biosynthesis will also be examined. Finally, a potential goal of this review is to explore the effects of NO on steroid model for the interaction of hypoxia on NO synthesis and production and further, to discern its source(s) and steroid production is proposed. mechanism of action. Attention will be given to the Journal of Endocrinology (2011) 210, 259–269 Introduction NO and steroidogenesis The initial rate-limiting step in steroidogenesis involves Nitric oxide (NO) is a diatomic free-radical gas involved in a cholesterol transport to the inner mitochondrial membrane number of physiologic processes (Moncada & Palmer 1991, by steroidogenic acute regulatory protein (StAR) and its Moncada et al.1991) and is synthesized from L-arginine by a binding partner, peripheral benzodiazepine receptor.
    [Show full text]
  • NMDA Agonists Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of NMDA Agonists Using ALZET Osmotic Pumps Aspartic Acid P7453: M. Domercq, et al. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia 2005;52(1):36-46 ALZET Comments: Oligonucleotide, antisense; oligonucleotide sense; kainate, dihydro-; aspartic acid, DL-threo-B-benzyloxy-; Saline, sterile; CSF/CNS (optic nerve); Rabbit; 1003D; 3 days; Controls received mp w/ vehicle, or contralateral nerves; antisense (glutamate transporters GLAST + GLT-1); animal info (adult, male, white New Zealand). P6888: J. Darman, et al. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. Journal of Neuroscience 2004;24(34):7566-7575 ALZET Comments: Aspartic acid, dl-threo-B-hydroxy; spermine, 1-naphthyl acetyl; CSF/CNS (intrathecal, subarachnoid space); Rat; 1007D; 7 days; Controls received mp w/ saline; enzyme inhibitors (GLT-1, GluR2). P3908: A. Hirata, et al. AMPA receptor-mediated slow neuronal death in the rat spinal cord induced by long-term blockade of glutamate transporters with THA. Brain Research 1997;771(37-44 ALZET Comments: Aspartic acid, dl-threo-B-hydroxy; Glutamate, l-; CSF, artificial;; CSF/CNS (subarachnoid space, intrathecal); Rat; 2ML1; no duration posted; dose-response; cannula position verified. P0289: R. M. Mangano, et al. Chronic infusion of endogenous excitatory amino acids into rat striatum and hippocampus. Brain Res. Bull 1983;10(47-51 ALZET Comments: Aminobutyric acid, Y-; Aspartic acid, dl-threo-B-hydroxy; Aspartic acid, l-; Cysteine sulfinic acid; Glutamic acid, l-; Radio-isotopes; 3H tracer; Acetate; Saline; CSF/CNS (corpus striatum); CSF/CNS (hippocampus); Rat; 2002; 2 weeks; comparison of injec.
    [Show full text]
  • Amino Acid Transport Pathways in the Small Intestine of the Neonatal Rat
    Pediat. Res. 6: 713-719 (1972) Amino acid neonate intestine transport, amino acid Amino Acid Transport Pathways in the Small Intestine of the Neonatal Rat J. F. FITZGERALD1431, S. REISER, AND P. A. CHRISTIANSEN Departments of Pediatrics, Medicine, and Biochemistry, and Gastrointestinal Research Laboratory, Indiana University School of Medicine and Veterans Administration Hospital, Indianapolis, Indiana, USA Extract The activity of amino acid transport pathways in the small intestine of the 2-day-old rat was investigated. Transport was determined by measuring the uptake of 1 mM con- centrations of various amino acids by intestinal segments after a 5- or 10-min incuba- tion and it was expressed as intracellular accumulation. The neutral amino acid transport pathway was well developed with intracellular accumulation values for leucine, isoleucine, valine, methionine, tryptophan, phenyl- alanine, tyrosine, and alanine ranging from 3.9-5.6 mM/5 min. The intracellular accumulation of the hydroxy-containing neutral amino acids threonine (essential) and serine (nonessential) were 2.7 mM/5 min, a value significantly lower than those of the other neutral amino acids. The accumulation of histidine was also well below the level for the other neutral amino acids (1.9 mM/5 min). The basic amino acid transport pathway was also operational with accumulation values for lysine, arginine and ornithine ranging from 1.7-2.0 mM/5 min. Accumulation of the essential amino acid lysine was not statistically different from that of nonessential ornithine. Ac- cumulation of aspartic and glutamic acid was only 0.24-0.28 mM/5 min indicating a very low activity of the acidic amino acid transport pathway.
    [Show full text]
  • Metabolites Involved in Glycolysis and Amino Acid Metabolism Are Altered in Short Children Born Small for Gestational Age
    nature publishing group Basic Science Investigation Articles Metabolites involved in glycolysis and amino acid metabolism are altered in short children born small for gestational age Philip G. Murray1,2, Imogen Butcher1,2, Warwick B. Dunn1,3,4, Adam Stevens1,2, Reena Perchard1,2, Daniel Hanson1,2, Andrew Whatmore1,2, Melissa Westwood1,5 and Peter E. Clayton1,2 BACKGROUND: Later life metabolic dysfunction is a well- SGA will fail to show catch-up growth over the first 2 y of life, recognized consequence of being born small for gestational leaving approximately 1,600 children in the United Kingdom age (SGA). This study has applied metabolomics to identify who remain short (height standard deviation score (SDS) <-2) whether there are changes in these pathways in prepubertal at 2 y of age (4). As well as growth impairment children born short SGA children and aimed to compare the intracellular and SGA are at increased risk of cardiovascular disease, hyperten- extracellular metabolome in fibroblasts derived from healthy sion, hyperlipidaemia, and type 2 diabetes in adulthood (5). children and SGA children with postnatal growth impairment. The causes of children being born SGA are numerous and METHODS: Skin fibroblast cell lines were established from include maternal, placental, and fetal factors (5). There are a small eight SGA children (age 1.8–10.3 y) with failure of catch-up number of monogenic causes for a child to be born SGA and growth and from three healthy control children. Confluent cells experience poor postnatal growth (e.g., 3-M syndrome, Bloom were incubated in serum-free media and the spent growth syndrome, Microcephalic Osteodysplastic dwarfism type II, medium (metabolic footprint), and intracellular metabolome IGF-IR mutations, Seckel syndrome, and Mulibrey nanism) (6).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0172909 A1 Nishibori Et Al
    US 20100172909A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0172909 A1 Nishibori et al. (43) Pub. Date: Jul. 8, 2010 (54) CEREBRAL EDEMA SUPPRESSANT (30) Foreign Application Priority Data (76) Inventors: Masahiro Nishibori, Okayama-shi Oct. 24, 2005 (JP) ................................. 2005-3O8949 (JP); Shuji Mori, Okayama-shi (JP); Hideo Takahashi, Okayama-shi (JP); Yasuko Publication Classification Tomono, Okayama-shi (JP): Naoto (51) Int. Cl. Adachi, Kyoto-shi (JP); Keyue Liu, A 6LX 39/395 (2006.01) Touon-shi (JP) A6IP 43/00 (2006.01) Correspondence Address: WENDEROTH, LIND & PONACK, L.L.P. (52) U.S. Cl. ..................................................... 424/139.1 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503 (US) (21) Appl. No.: 12/634,790 (57) ABSTRACT (22) Filed: Jan. 4, 2010 The objective to be solved by the present invention is to provide a method for effectively suppressing cerebral edema. Related U.S. Application Data The method for Suppressing cerebral edema according to the (63) Continuation-in-part of application No. 12/084,044, present invention is characterized in comprising a step of filed on Apr. 24, 2008, now abandoned, filed as appli administering an anti-HMGB 1 antibody recognizing cation No. PCT/JP2006/320436 on Oct. 13, 2006. 208EEEDDDDE215 (SEQID NO: 1) as an HMGB1 epitope. 8:38-3::::::isis: 88 grogg A:::::::::38: 38t:3{xy 38:::::sier88 gro.3 Patent Application Publication Jul. 8, 2010 Sheet 1 of 4 US 2010/0172909 A1 es O O C wa o c O V v (D 92 s. ON- I - o its 5 wn a 9 - Yee v O Y O ea 5 O O NY O CC o S O .
    [Show full text]
  • Reproductive Biology and Endocrinology Biomed Central
    Reproductive Biology and Endocrinology BioMed Central Research Open Access Opposing effects of D-aspartic acid and nitric oxide on tuning of testosterone production in mallard testis during the reproductive cycle Maria M Di Fiore*1, Claudia Lamanna1, Loredana Assisi2 and Virgilio Botte2 Address: 1Department of Life Sciences, Second University of Naples, via Vivaldi 43, 81100 Caserta, Italy and 2Department of Zoology, University of Naples 'Federico II', via Mezzocannone 8, 80134 Naples, Italy Email: Maria M Di Fiore* - [email protected]; Claudia Lamanna - [email protected]; Loredana Assisi - [email protected]; Virgilio Botte - [email protected] * Corresponding author Published: 4 July 2008 Received: 28 February 2008 Accepted: 4 July 2008 Reproductive Biology and Endocrinology 2008, 6:28 doi:10.1186/1477-7827-6-28 This article is available from: http://www.rbej.com/content/6/1/28 © 2008 Di Fiore et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: D-Aspartic acid (D-Asp) and nitric oxide (NO) play an important role in tuning testosterone production in the gonads of male vertebrates. In particular, D-Asp promotes either the synthesis or the release of testosterone, whereas NO inhibits it. In this study, we have investigated for the first time in birds the putative effects of D-Asp and NO on testicular testosterone production in relation to two phases of the reproductive cycle of the adult captive wild- strain mallard (Anas platyrhynchos) drake.
    [Show full text]
  • Systemic L-Kynurenine Administration Partially Protects Against NMDA
    Systemic L-Kynurenine Administration Partially Protects Against NMDA, But Not Kainate-Induced Degeneration of Retinal Ganglion Cells, and Reduces Visual Discrimination Deficits in Adult Rats Christian K. Vonuerk* MichaelR. Kreutz* Evan B. Dreyer,-f and Bernhard A. Sabel* Purpose. Kynurenic acid (KYNA), an endogenous tryptophan metabolite, is an N-methyl-D- aspartate (NMDA) antagonist active at the glycine-binding site of the NMDA-receptor com- plex. The authors investigated whether systemic administration of a biochemical precursor of KYNA, L-kynurenine (L-Kyn), could block NMDA- or kainic acid (KA)-induced cell death in adult rat retinal ganglion cells (RGCs) and protect NMDA-treated animals from lesion- induced visual deficits. Methods. Rats were injected with 20-nmol NMDA or 5-nmol KA intraocularly. To quantify the number of surviving RGCs, the retrograde tracer horseradish-peroxidase was injected into the superior colliculus contralateral to the lesioned eye. Surviving RGCs were counted on wholemounted retinae in a centroperipheral gradient, as well as in the four quadrants, using a computer-assisted image analysis system. Results. The NMDA-injections resulted in an approximately 82% RGC loss in the adult rat retina compared with control retinae and a cell loss of approximately 50% in KA-treated retinae. Pretreatment with L-Kyn significantly reduced NMDA-induced RGC degeneration to values of approximately 60%, but KA toxicity was not significantly affected by L-Kyn pretreat- ment. Intraocular injections of NMDA resulted in an impairment of visual discrimination behavior, which partially recovered within a period of approximately 3 weeks. However, when treated systemically with L-Kyn, brightness discrimination was significantly improved as com- pared with NMDA-treated rats.
    [Show full text]
  • 24Amino Acids, Peptides, and Proteins
    WADEMC24_1153-1199hr.qxp 16-12-2008 14:15 Page 1153 CHAPTER COOϪ a -h eli AMINO ACIDS, x ϩ PEPTIDES, AND NH3 PROTEINS Proteins are the most abundant organic molecules 24-1 in animals, playing important roles in all aspects of cell structure and function. Proteins are biopolymers of Introduction 24A-amino acids, so named because the amino group is bonded to the a carbon atom, next to the carbonyl group. The physical and chemical properties of a protein are determined by its constituent amino acids. The individual amino acid subunits are joined by amide linkages called peptide bonds. Figure 24-1 shows the general structure of an a-amino acid and a protein. α carbon atom O H2N CH C OH α-amino group R side chain an α-amino acid O O O O O H2N CH C OH H2N CH C OH H2N CH C OH H2N CH C OH H2N CH C OH CH3 CH2OH H CH2SH CH(CH3)2 alanine serine glycine cysteine valine several individual amino acids peptide bonds O O O O O NH CH C NH CH C NH CH C NH CH C NH CH C CH3 CH2OH H CH2SH CH(CH3)2 a short section of a protein a FIGURE 24-1 Structure of a general protein and its constituent amino acids. The amino acids are joined by amide linkages called peptide bonds. 1153 WADEMC24_1153-1199hr.qxp 16-12-2008 14:15 Page 1154 1154 CHAPTER 24 Amino Acids, Peptides, and Proteins TABLE 24-1 Examples of Protein Functions Class of Protein Example Function of Example structural proteins collagen, keratin strengthen tendons, skin, hair, nails enzymes DNA polymerase replicates and repairs DNA transport proteins hemoglobin transports O2 to the cells contractile proteins actin, myosin cause contraction of muscles protective proteins antibodies complex with foreign proteins hormones insulin regulates glucose metabolism toxins snake venoms incapacitate prey Proteins have an amazing range of structural and catalytic properties as a result of their varying amino acid composition.
    [Show full text]